Aadi Bioscience (AADI) Competitors $1.60 -0.02 (-1.23%) As of 08/15/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AADI vs. CYBN, LYEL, MEIP, LFVN, CTNM, TVGN, ACTU, GLSI, ELDN, and RAPTShould you be buying Aadi Bioscience stock or one of its competitors? The main competitors of Aadi Bioscience include Cybin (CYBN), Lyell Immunopharma (LYEL), MEI Pharma (MEIP), Lifevantage (LFVN), Contineum Therapeutics (CTNM), Semper Paratus Acquisition (TVGN), Actuate Therapeutics (ACTU), Greenwich LifeSciences (GLSI), Eledon Pharmaceuticals (ELDN), and Rapt Therapeutics (RAPT). These companies are all part of the "pharmaceutical products" industry. Aadi Bioscience vs. Its Competitors Cybin Lyell Immunopharma MEI Pharma Lifevantage Contineum Therapeutics Semper Paratus Acquisition Actuate Therapeutics Greenwich LifeSciences Eledon Pharmaceuticals Rapt Therapeutics Aadi Bioscience (NASDAQ:AADI) and Cybin (NYSE:CYBN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment. Is AADI or CYBN more profitable? Cybin has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Cybin's return on equity of -37.58% beat Aadi Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Aadi Bioscience-246.06% -71.87% -57.28% Cybin N/A -37.58%-36.59% Which has preferable earnings and valuation, AADI or CYBN? Cybin has lower revenue, but higher earnings than Aadi Bioscience. Cybin is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAadi Bioscience$25.07M1.58-$65.76M-$2.35-0.68CybinN/AN/A-$57.88M-$4.60-1.50 Do analysts rate AADI or CYBN? Aadi Bioscience presently has a consensus target price of $1.67, indicating a potential upside of 4.17%. Cybin has a consensus target price of $85.00, indicating a potential upside of 1,128.50%. Given Cybin's stronger consensus rating and higher possible upside, analysts plainly believe Cybin is more favorable than Aadi Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Do institutionals and insiders believe in AADI or CYBN? 52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by insiders. Comparatively, 15.0% of Cybin shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media prefer AADI or CYBN? In the previous week, Cybin had 3 more articles in the media than Aadi Bioscience. MarketBeat recorded 3 mentions for Cybin and 0 mentions for Aadi Bioscience. Cybin's average media sentiment score of 0.24 beat Aadi Bioscience's score of 0.00 indicating that Cybin is being referred to more favorably in the news media. Company Overall Sentiment Aadi Bioscience Neutral Cybin Neutral Which has more volatility and risk, AADI or CYBN? Aadi Bioscience has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Cybin has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. SummaryCybin beats Aadi Bioscience on 10 of the 15 factors compared between the two stocks. Get Aadi Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for AADI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AADI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AADI vs. The Competition Export to ExcelMetricAadi BiosciencePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.52M$822.76M$5.71B$9.79BDividend YieldN/A4.84%3.77%4.10%P/E Ratio-0.701.1830.9125.28Price / Sales1.5825.65404.2188.50Price / CashN/A19.5625.2228.45Price / Book0.376.599.536.01Net Income-$65.76M-$4.67M$3.26B$265.34M7 Day Performance-8.57%1.22%4.66%2.89%1 Month Performance-13.51%0.61%5.35%1.61%1 Year Performance8.84%15.33%32.14%25.61% Aadi Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AADIAadi Bioscience0.5079 of 5 stars$1.60-1.2%$1.67+4.2%+8.8%$39.52M$25.07M-0.7040CYBNCybin2.4415 of 5 stars$7.26-2.6%$85.00+1,070.8%N/A$171.26MN/A-1.6650Positive NewsLYELLyell Immunopharma3.2969 of 5 stars$10.58-3.6%$15.00+41.8%-56.6%$169.72M$60K-0.42270Earnings ReportAnalyst DowngradeMEIPMEI Pharma1.952 of 5 stars$4.83-6.9%N/A+54.3%$167.99M$65.30M-1.02100Gap UpLFVNLifevantage4.13 of 5 stars$13.76+3.5%$30.50+121.7%+68.0%$167.42M$200.16M19.94260Positive NewsCTNMContineum Therapeutics3.4757 of 5 stars$6.43-0.6%$22.50+249.9%-56.9%$167.39M$50M-2.9231News CoverageAnalyst ForecastShort Interest ↓TVGNSemper Paratus Acquisition3.7509 of 5 stars$0.98+8.8%$10.00+920.4%+35.5%$165.60MN/A0.003Analyst ForecastACTUActuate Therapeutics2.2567 of 5 stars$8.01-0.1%$20.50+155.9%-6.7%$164.17MN/A0.0010Earnings ReportAnalyst ForecastGLSIGreenwich LifeSciences1.374 of 5 stars$12.49+2.5%$39.00+212.2%-12.5%$162.83MN/A-9.913Earnings ReportELDNEledon Pharmaceuticals1.8719 of 5 stars$2.71-0.4%$10.00+269.0%-3.7%$162.58MN/A-1.2910Earnings ReportShort Interest ↑RAPTRapt Therapeutics4.6005 of 5 stars$9.55-2.7%$21.43+124.4%-33.0%$162.24M$1.53M-0.6780 Related Companies and Tools Related Companies CYBN Competitors LYEL Competitors MEIP Competitors LFVN Competitors CTNM Competitors TVGN Competitors ACTU Competitors GLSI Competitors ELDN Competitors RAPT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AADI) was last updated on 8/18/2025 by MarketBeat.com Staff From Our Partners"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aadi Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aadi Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access